LoadingLoadingLoadingNet selling: insiders sold $1.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Two Sigma
$63.5M
added
Millennium
$38.0M
added
D.E. Shaw
$96.4M
bought
No tracked top-trader positions in IBRX as of Oct 24, 10:09 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.08 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
-$0.09 to $0.00
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$0.22 / -$0.08Yahoo Finance | -$0.14 miss | $51.2M No estimate | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$0.08 / -$0.07Yahoo Finance | -$0.01 miss | $44.2M No estimate | Unavailable |
| Dec 31, 2025 | Feb 23, 2026 | -$0.06 / -$0.10Yahoo Finance | +$0.04 beat | $38.3M No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | -$0.07 / -$0.10Yahoo Finance | +30.00% beat | $32.1M No estimate | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | -$0.10 / -$0.10Alpha Vantage | +0.00% in line | $26.4M No estimate | Unavailable |
| Mar 31, 2025 | May 12, 2025 | -$0.15 / -$0.16Alpha Vantage | +6.25% beat | $16.5M No estimate | Unavailable |
| Dec 31, 2024 | Mar 3, 2025 | -$0.08 / -$0.13Alpha Vantage | +38.46% beat | $7.6M No estimate | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | -$0.12 / -$0.18Alpha Vantage | +33.33% beat | $6.1M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $32.1M | $38.3M | $44.2M | $51.2M |
| Cost of what it sold | $4.1M | $4.2M | $238.0K | $298.0K |
| Gross profit | $27.9M | $34.0M | $44.0M | $50.9M |
| What it spent | ||||
| Research and development | $50.7M | $60.8M | $64.8M | $57.7M |
| Sales and admin | $36.3M | $38.7M | $45.8M | $51.8M |
| Other operating costs | -$3.5M | — | $3.2M | $3.1M |
| Total operating expenses | $83.6M | $98.7M | $113.8M | $112.6M |
| What was left | ||||
| Operating profit | -$55.6M | -$64.7M | -$69.8M | -$61.7M |
| Interest on debt | $27.6M | $27.2M | $28.5M | $20.0K |
| Profit before tax | -$67.3M | -$62.1M | -$632.8M | -$230.4M |
| Tax | -$35.0K | -$135.0K | -$9.0K | — |
| Net profit | -$67.3M | -$61.9M | -$632.8M | -$230.4M |
| EBITDA | -$35.8M | -$31.0M | -$599.9M | -$226.0M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
BullishOct 21ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
BullishOct 21ImmunityBio completes database lock for bladder cancer trial
BullishOct 21ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
BullishOct 21IBRX Stock Rises: ImmunityBio Expects November Results For Anktiva Bladder Cancer Trial
BullishOct 21ImmunityBio reports 84 percent cystectomy avoidance. Six analysts rate ImmunityBio stock Buy
Leans bullishOct 20IBRX Stock Slips As Legal Probes Cloud Outlook
BearishOct 19ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
BullishOct 1911 macro signals shaping IBRX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
